Hepatocellular Carcinoma (HCC)JADENCT04510740
Liver Cancer Registry Platform
An observational study of Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma, run by iOMEDICO AG at 1 site in Germany.
Trial summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
- What is being tested?
- Physician's choice according to patient's needs.
- How many people
- 1,000 participants
- Where
- 1 siteGermany
- Study dates
- 9 Aug 2020to Dec 2027
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with hepatocellular carcinoma (HCC), or cholangiocarcinoma (CCC) starting treatment for early, intermediate or advanced disease
Who may be able to join
- Confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) als early, intermediate or advanced/metastatic stage
- Age ≥ 18 years
- Signed and dated informed consent (IC):
- For participation in the PRO module: Before primary locoregional therapy or start of first systemic treatment
- For no participation in the PRO module: No later than 8 weeks after primary locoregional therapy or start of first systemic treatment
Who cannot join
- Patients treated with best supportive care (BSC) only (i.e. no surgery, no radiotherapy, no ablative procedures, no systemic anti-tumoral therapies)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: JADE - Clinical Research Platform on Treatment and Outcome in Patients With Hepatocellular or Cholangiocellular Cancer
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC) in Germany.
Read the detailed description
JADE is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of HCC or CCC in Germany. The registry will follow patients for up to three years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
Health-related quality of life in patients with HCC / CCC will be evaluated for up to three years.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
- Being tested
- Physician's choice according to patient's needs.
- Medical subject headings
- Carcinoma, Hepatocellular, Cholangiocarcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Physician's choice according to patient's needs.Other
Routine care as per site standard.
| Study group | Role | What they receive |
|---|---|---|
| Hepatocellular Carcinoma (HCC) | Patients with Hepatocellular Carcinoma (HCC) Receives: Other: Physician's choice according to patient's needs. | |
| Cholangiocarcinoma (CCC) | Patients with Cholangiocarcinoma (CCC) Receives: Other: Physician's choice according to patient's needs. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Course of treatment (treatment reality).
Documentation of anamnestic data and therapy sequences.
Measured: 3 years per patient.
Secondary outcomes (5)
Best Response.
Documentation of response rates per line of treatment.
Measured: 3 years per patient.
Progression-free survival.
Documentation of progression-free survival per line of treatment.
Measured: 3 years per patient.
Overall survival.
Documentation of overall survival per line of treatment.
Measured: 3 years per patient.
Health-related quality of life (Patient-reported outcome, PRO).
EORTC QLQ-C30 core questionnaire [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high scale score represents a higher response level: (a) global health status: a high score represents high quality of life, (b) functional scales: a high score represents high/healthy level of functioning, (c) symptom scales/items: a high score represents high level of symptomatology or problems]
Measured: 3 years per patient.
Carcinoma Health-related quality of life (Patient-reported outcome, PRO).
EORTC QLQ-HCC18, the hepatocellular carcinoma specific module / EORTC QLQ-BIL21, the cholangiocarcinoma specific module [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high score for scales and single items represents a high level of symptomatology or problems].
Measured: 3 years per patient.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2020
- Study start9 Aug 2020
- Primary completionSep 2026 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular Carcinoma (HCC)Studies of the same condition, open and under way.
- More trials run by iOMEDICO AGThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- iOMEDICO AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Thomas Berg, Prof.Dr., Study chair, LeipzigPeter R. Galle, Prof.Dr., Study chair, MainzWolf P. Hofmann, Prof.Dr., Study chair, BerlinAchim Kautz, Study chair, KölnPhilippe Pereira, Prof.Dr., Study chair, HeilbronnKarin Potthoff, Dr., Study chair, Freiburg im BreisgauJan Schröder, PD Dr., Study chair, Mülheim an der RuhrRobert Thimme, Prof.Dr., Study chair, Freiburg im Breisgau
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04510740
- Sponsor's protocol ID
- IOM-100425
- Acronym
- JADE
- Status last verified
- Aug 2026
- First submitted
- 10 Aug 2020
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- JADE - Clinical Research Platform on Treatment and Outcome in Patients With Hepatocellular or Cholangiocellular Cancer
- ClinicalTrials.gov ID
- NCT04510740
- Acronym / sponsor ID
- JADE / IOM-100425
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- iOMEDICO AGIndustry (pharma, biotech, devices)
- Study start
- 9 Aug 2020 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 12 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC) in Germany.
Detailed description
JADE is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of HCC or CCC in Germany. The registry will follow patients for up to three years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
Health-related quality of life in patients with HCC / CCC will be evaluated for up to three years.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Hepatocellular Carcinoma (HCC) | – | Other: Physician's choice according to patient's needs.Patients with Hepatocellular Carcinoma (HCC) |
| Cholangiocarcinoma (CCC) | – | Other: Physician's choice according to patient's needs.Patients with Cholangiocarcinoma (CCC) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with hepatocellular carcinoma (HCC), or cholangiocarcinoma (CCC) starting treatment for early, intermediate or advanced disease
Key inclusion criteria (5 listed)
- Confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) als early, intermediate or advanced/metastatic stage
- Age ≥ 18 years
- Signed and dated informed consent (IC):
Key exclusion criteria (1 listed)
- Patients treated with best supportive care (BSC) only (i.e. no surgery, no radiotherapy, no ablative procedures, no systemic anti-tumoral therapies)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Physician's choice according to patient's needs.Routine care as per site standard. | Other | Cholangiocarcinoma (CCC), Hepatocellular Carcinoma (HCC) |
Primary outcome
Course of treatment (treatment reality).
Time frame: 3 years per patient.
Documentation of anamnestic data and therapy sequences.
5 secondary outcomes
Best Response.
Time frame: 3 years per patient.
Progression-free survival.
Time frame: 3 years per patient.
Overall survival.
Time frame: 3 years per patient.
Health-related quality of life (Patient-reported outcome, PRO).
Time frame: 3 years per patient.
Carcinoma Health-related quality of life (Patient-reported outcome, PRO).
Time frame: 3 years per patient.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
Related trials for Hepatocellular Carcinoma (HCC)
Recruiting
Improving Hepatocellular Carcinoma Screening
Magnetic Resonance Imaging, Hepatocellular Carcinoma
RecruitingObservational study
DNP-MRSI of HCC Metabolism to Predict Therapeutic Response
Barcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC, Hepatocellular Carcinoma (HCC)
Recruiting
Targeted Navigation in Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma, Cholangiocarcinoma
RecruitingPhase 2/3
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
HCC
Active, not recruitingPhase 2
TheraSphere With Durvalumab and Tremelimumab for HCC
Hepatocellular Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thomas Berg, Prof.Dr. study chair
Leipzig
Peter R. Galle, Prof.Dr. study chair
Mainz
Wolf P. Hofmann, Prof.Dr. study chair
Berlin
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma, run by iOMEDICO AG at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Course of treatment (treatment reality). (time frame: 3 years per patient.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.